Medicus Pharma initiated with a Buy at Brookline

Brookline analyst Kumaraguru Raja initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $12 price target Medicus is advancing D-MNA, a doxorubicin tip loaded dissolvable microarray needle array skin patch, in basal cell carcinoma through its subsidiary SkinJect, notes the firm, which sees a favorable risk-reward as D-MNA advances through the clinic. A Phase 2 trial is ongoing in nodular basal cell carcinoma at nine clinical sites in the United States and an interim data analysis from the Phase 2 trial is expected in Q1 of 2025, the analyst noted.